Adagio medical fulcrum-vt u.s. pivotal study acute results to be presented in late-breaking session at vt symposium

Laguna hills, calif.--(business wire)--adagio medical holdings, inc. (nasdaq: adgm) (“adagio” or “the company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that acute results from the company's fulcrum-vt u.s. pivotal study have been accepted for presentation in a late-breaking clinical science session at the 20th annual international symposium on ventricular arrhythmias, being held from october 10- 11, 2025 at the philadelphi.
ADGM Ratings Summary
ADGM Quant Ranking